The current study demonstrates for the first time that IDO is expressed on CTCs and suggests that IDO+ CTCs and particularly the IDO+/PD-L1- subset may have prognostic relevance in patients with NSCLC treated with anti-PD-1 immunotherapy. Here, PDCD1 is linked to non-small cell lung carcinoma.